Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: Prevalence, Complications, and Challenges in à Resource-Limited Setting

Abstract

Rahma Guesmi and Zohra Jellali

Introduction: Secondary hyperparathyroidism (SHPT) is a serious complication of end-stage renal disease. Despite its high morbidity and mortality, it remains a controllable condition if managed early.

Methods: We conducted a cross-sectional study at the hemodialysis unit of Sidi Bouzid hospital. All patients undergoing hemodialysis for more than six months were included. Clinical, biochemical, and therapeutic data were collected and analyzed.

Résults: A total of 94 patients were included. SHPT was present in approximately 60% of patients. More than 50% of patients suffered from bone demineralization, pruritus, vascular calcifications, and resistant anemia. None of the patients received calcimimetics or non-calcium phosphate binders. However, 80% were on calcium-based phosphate binders, and 7% underwent subtotal parathyroidectomy.

Conclusion: SHPT affects more than half of our dialysis population and is associated with severe complications. In low-income countries with limited treatment options, innovative approaches such as artificial intelligence could help improve disease management and patient outcomes.

PDF